A new startup thinks it's found a key to drugging 'disordered' proteins — and it has plenty of cash to get started
The saying goes necessity is the mother of invention — and few areas of drug development are in greater need than oncology. A new startup is now repurposing promising technology to tackle the hardest-to-drug proteins, and a suite of big-name backers are buying in.
Ambagon Therapeutics launched Friday with an $85 million A round and a world-class group of researcher-founders building what are known as “molecular glues” to crack the code on a class of elusive cellular proteins, the biotech said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.